Skip to main content
Premium Trial:

Request an Annual Quote

Precipio Diagnostics Prices $2.7M Direct Offering

NEW YORK (GenomeWeb) – Precipio Diagnostics announced today that it has priced a $2.7 million registered direct offering of equity units.

According to the company, it will offer for sale 2,748 units, each consisting of one share of Series C preferred stock convertible at $1.40 per share, and warrants to purchase up to roughly 1.9 million shares of common stock at an exercise price of $1.63 per share.

Aegis Capital is acting as the sole placement agent for the offering, which is expected to take place on or around Nov. 6.

New Haven, Connecticut-based Precipio offers molecular diagnostic tests for cancer and a service called SmartPath, which matches a patient and their treating physician with an academic expert from the Yale School of Medicine to provide a second-opinion pathology report. It recently acquired Transgenomic and its ICE COLD-PCR diagnostics platform.

During midday trading on the Nasdaq, shares of Precipio were down 15 percent to $1.38.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.